Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
A phase 1/2 trial of Lenvatinib, Envafolimab, Sunitinib in non-small-cell lung cancer and small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
Overview
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05024214 by 3D Medicines (Sichuan) Co., Ltd., with 170 participants planned, started 2021-11-15 and due to reach its primary completion in 2026-12. Interventions recorded: Lenvatinib + Envafolimab, Sunitinib. Conditions listed: Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Shares Envafolimab, Lenvatinib.
- TrialGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Shares Lenvatinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of NDI 1150-101 in Patients With Solid Tumors
Shares Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialCLEAR (KEYNOTE-581)
Shares Sunitinib, Lenvatinib, Renal cell carcinoma.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Renal cell carcinoma, Hepatocellular carcinoma, Non-small-cell lung cancer.
- TrialLEAP-002
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialPhase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Shares Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Beta-only IL-2 ImmunoTherapY Study
Shares Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.